Selecta Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview

Cartesian Therapeutics

01/05/2023 16:50

* Selecta Biosciences Inc  SELB.OQ   SELB.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4. 
    * The Watertown Massachusetts-based  company is expected to
report
 a 65.2% decrease in revenue to $11.833 million from $34 million
a year ago, according to the mean estimate from 7 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Selecta Biosciences
Inc
is for a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $6​, above​ its last closing price of $1.19.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.08       -0.07      0.04      Beat    154.9
 Sep. 30 2022  0.03        -0.01      -0.05     Missed  -775.7
 Jun. 30 2022  -0.06       -0.08      0.06      Beat    177.8​
 Mar. 31 2022  -0.10       -0.11      0.23      Beat    312.3
 ​​Dec.        -0.08       -0.07      0.03      Beat    141.2
 31 2021                                                
 Sep. 30 2021  -0.03       -0.07      -0.16     Missed  -115.4
                                                        ​
 Jun. 30 2021  -0.13       -0.12      0.04      Beat    134.1
 Mar. 31 2021  -0.10       -0.12      -0.22     Missed  -80.3
 This summary was machine generated May 1 at 15:50 GMT.  All
figures in US dollars  unless otherwise stated